STRATA SKIN SCIENCES INC

NASDAQ: SSKN (Strata Skin Sciences, Inc.)

Last update: 04 May, 1:29AM

2.63

-0.07 (-2.59%)

Previous Close 2.70
Open 2.65
Volume 2,398
Avg. Volume (3M) 2,583
Market Cap 10,970,151
Price / Sales 0.260
Price / Book 35.41
52 Weeks Range
2.51 (-4%) — 4.70 (78%)
Earnings Date 5 May 2025 - 9 May 2025
Profit Margin -27.22%
Operating Margin (TTM) -29.58%
Diluted EPS (TTM) -2.27
Quarterly Revenue Growth (YOY) 0.90%
Total Debt/Equity (MRQ) 614.35%
Current Ratio (MRQ) 1.05
Levered Free Cash Flow (TTM) 1.80 M
Return on Assets (TTM) -7.60%
Return on Equity (TTM) -151.23%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Mixed
Medical Devices (Global) Mixed Bearish
Stock Strata Skin Sciences, Inc. Mixed Bearish

AIStockmoo Score

-0.3
Analyst Consensus NA
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages -1.0
Technical Oscillators 2.0
Average -0.33

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SSKN 11 M - - 35.41
QDEL 2 B - - 0.780
AHCO 1 B - 15.61 0.800
IART 1 B - - 1.05
INMD 1 B - 6.73 1.55
BBNX 549 M - - 2.95

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

Sector Healthcare
Industry Medical Devices
Investment Style Small Value
% Held by Insiders 4.02%
% Held by Institutions 64.08%

Ownership

Name Date Shares Held
Financial Perspectives, Inc 31 Mar 2025 101

No data within this time range.

No data within this time range.

Date Type Details
14 Oct 2025 Announcement Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
03 Oct 2025 Announcement Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
30 Sep 2025 Announcement STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
22 Sep 2025 Announcement New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences’ Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach
04 Sep 2025 Announcement STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements
04 Sep 2025 Announcement STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering
03 Sep 2025 Announcement STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules
02 Sep 2025 Announcement STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination Therapies of Its XTRAC Excimer Laser with JAK Inhibitors, Systemic and Biologic Drugs, Bolstering Expansion into New Indications Like Vitiligo and Other Auto-Immune Skin Conditions
02 Sep 2025 Announcement STRATA Skin Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
13 Aug 2025 Announcement STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
07 Aug 2025 Announcement STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients
31 Jul 2025 Announcement STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria